biotech / news / / India Today
Eli Lilly's diabetes and obesity drug Mounjaro has emerged as the world's top-selling medicine, overtaking Merck’s blockbuster cancer therapy Keytruda.
Eli Lilly’s Mounjaro surpassed Merck’s Keytruda as the world’s top-selling medicine in 2026.
KEY POINTS
- Mounjaro generated $8.7 billion in global sales in Q1 2026, exceeding Keytruda’s $7.9 billion.
- Despite cheaper semaglutide generics, Mounjaro remains India’s highest-selling drug by value since October 2025.
- Combined tirzepatide portfolio sales for Lilly reached $36.5 billion in 2025, well above Keytruda’s $31.6 billion.
- Lilly views India as a high-growth market and potential export hub for Mounjaro.
COMPANIES
Summarized by Newsio from India Today. How we summarize →